

May 29, 2017

To	To
NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051	BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sirs,

SUB: Press Release – Reg.

We enclose copy of the Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**


B.ADI REDDY
Company Secretary



NEWS RELEASE

29th May 2017, Hyderabad, India

Aurobindo Pharma Ltd Q4 FY16-17 and FY16-17 Financial Results

Company has adopted Indian Accounting Standards (Ind AS) from 1st April 2016 and hence the financials are prepared in accordance with the reporting structure prescribed by Section 133 of the Company's Act 2013. For comparison purpose Q4 FY15-16 financials are also restated as per Ind AS.

Amount in INR Cr	Q4 FY16-17	Q4 FY15-16	% Chg	FY16-17	FY15-16	% Chg
Consolidated Operating Income (incl excise duty)*	3,641.6	3,745.9	-2.8	15,089.9	13,955.2	8.1
EBITDA before Forex and Other income	721.2	866.3	-16.7	3,434.3	3,188.1	7.7
EBITDA %	19.8%	23.1%		22.8%	22.8%	
PBT	647.7	761.0	-14.9	3,055.8	2,742.8	11.4
PAT (after JV share, minority interest and OCI)	532.9	554.4	-3.9	2,295.9	2,023.6	13.4

*As per Ind AS excise duty is a part of raw material cost; OCI: Other Comprehensive Income

Consolidated Performance for FY16-17 (Audited) on YoY basis:

- Operating Income up by 8% to INR 15,090 Cr vs INR 13,955 Cr
- EBITDA before Forex and Other income up 8% to INR 3,434 Cr vs INR 3,188 Cr; EBITDA margin is at 22.8%
- PAT after JV share, minority interest and OCI up by 13% to INR 2,296 Cr vs INR 2,024 Cr
- Basic & Diluted EPS is 39.33 per share respectively
- Received final approval for 61 ANDAs from USFDA
- Research and Development (R&D) spend at INR 543 Cr, 3.6% of revenue
- Formulations business registered a growth 9% at INR 12,045 Cr (80% of revenue)
- API business registered 5% growth at INR 3,042 Cr (20% of Sales).
- Board has considered and approved an interim dividend @ 125% i.e., INR 1.25 per equity share of INR 1/-. This is in addition to the interim dividends of 125% i.e., INR 1.25 per equity share of INR 1/- aggregating to 250% i.e. INR 2.5 per equity share of INR 1/- for FY16-17. The Board do not recommend any further dividend for the year FY16-17.

Consolidated Performance for Q4 FY16-17 on YoY basis:

- Operating Income at INR 3,642 Cr vs INR 3,746 Cr.
- EBITDA before Forex and Other income at INR 721 Cr vs INR 866 Cr; EBITDA margin at 19.8%.
- PAT after JV share, minority interest and OCI at INR 532.9 Cr as against INR 554.4 Cr in the corresponding previous period.
- Basic & Diluted EPS is INR 9.1 per share.
- Research & Development (R&D) spend at INR 146 Cr, 4.0% of revenues
- Received Final approval for 14 ANDAs and tentative approval for 2 ANDAs from USFDA.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said:

"We have registered 8% YoY revenue growth in FY17 despite a challenging environment in select markets. We continue to invest in building a differentiated and speciality product portfolio, which will sustain the growth momentum for the future."

Operational Performance (Consolidated):

Gross Sales (Amt in INR Cr)	Q4 FY16-17	Q4 FY15-16	% Chg (YoY)	FY16-17	FY15-16	% Chg (YoY)
Formulations						
USA	1,643.2	1,634.1	0.6	6,827.2	6,078.6	12.3
Europe	777.2	840.7	-7.6	3,277.1	3,130.4	4.7
Emerging Markets	197.1	163.0	20.9	755.6	646.1	17.0
ARV	261.9	328.4	-20.2	1,185.4	1,209.3	-2.0
Total Formulations	2,879.4	2,966.1	-2.9	12,045.4	11,064.4	8.9%
Active Pharmaceuticals Ingredients (API)						
Betalactum	512.1	502.0	2.0	2,043.4	1,856.5	10.1%
Non Betalactum	250.6	272.6	-8.0	998.6	1,027.0	-2.8%
Total API	762.8	774.6	-1.5	3,042.1	2,883.5	5.5%
Consolidated Gross Sales	3,642.2	3,740.7	-2.6	15,087.5	13,947.9	8.2%
Dossier Income	-0.6	5.3		2.4	7.4	
Gross Operating Income	3,641.6	3,745.9	-2.8	15,089.9	13,955.2	8.1%

Formulations

Formulations business for FY17 at INR 12,045 Cr, YoY growth of 9%, primarily on account of healthy growth in the US and Emerging markets. Formulation sales accounted for 80% of total revenues. For fourth quarter, the formulation sales was at Rs. 2,879 crore, a decline of 3% YoY and accounted for 79% to total revenues.

US Formulations

Sales from US for FY17 at INR 6,827 Cr, YoY growth of 12% and accounted 45% to the total revenues. In Q4 FY16-17, the sales was at INR 1,643 Cr as against INR 1,634 Cr for the previous corresponding quarter, registering an increase of 1% YoY. During the year, the company filed 31 ANDAs with USFDA including 19 in Oral and 12 in Injectable & Ophthalmic category. Of these, 8 ANDAs including 5 in the Oral category and 3 in the Injectable category filed in the fourth quarter.

During the quarter, the company received 16 ANDA approvals from USFDA including 14 Final approvals (4 tentative approvals received final approvals) and 2 tentative approvals. As on 31st March, 2017, on a cumulative basis, the company filed 429 ANDAs with USFDA and received approvals for 314 ANDAs including 38 tentative* approvals.

*Tentative approvals include 10 ANDAs approved under PEPFAR.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

EU Formulations

Sales from EU formulations for FY17 was at INR 3,277 Cr, an increase of 5% YoY. The business accounted for 22% of gross sales. For the Fourth quarter, the sales was INR 777 Cr as against INR 840.7 Cr in the corresponding previous period. The acquired Actavis business continue to witness profitability during the quarter. As on 31st Mar, 2017, we have transferred manufacturing of 69 products from Europe to India.

During the quarter, Agile Pharma B.V., Netherlands, a wholly owned step-down subsidiary of the Company acquired 100% stake in Portuguese Pharmaceutical Company - Generis Farmaceutica S.A. The acquisition have been completed in April 2017.

ARV formulations

The ARV business sales for FY17 was INR 1,185, declined 2% YoY and accounted for 8% of revenues. In Q4 FY16-17, the sales was at INR 262 Cr as against INR 328 Cr.

Emerging Markets formulations

Sales from Emerging markets formulations reported 17% YoY growth to INR 756 Cr in FY17 and accounted for ~5% of gross sales of the company. For the Fourth quarter, the business registered a healthy 21% YoY to INR 197 Cr.

API business

The Active Pharmaceuticals Ingredients business contributed 20% to the total revenue and registered a growth of 5% YoY to INR 3,042 in FY17. The strong growth in Betalactum APIs led to overall API growth. For the quarter, API sales down by 2% YoY to INR 763 Cr.

Geographical breakup

During the quarter, the gross sales to the international markets stood at INR 3,200 Cr and the domestic sales were at INR 443 Cr representing 88% and 12% respectively.

Global Regulatory Filings:

Filings	Q4 FY16-17	Cumulative Filings as on 31 st Mar 2017
ANDAs (including filings made from Aurobindo USA)	8	429
DMFs (including filings made from AuroNext and AuroPeptide)	7	220
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe. South Africa and Canada)	104	3,043
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	20	2,609

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

USFDA approvals received in Q4 FY16-17:

Final Approvals

1	Pravastatin Sodium Tab (Gx Pravachol®) 10, 20, 40 & 80mg	CVS
2	Fesoterodine Fumarate Extended-Release Tab (Gx Toviaz®) 4 & 8mg	Genitourinary
3	Rabeprazole Sodium Delayed-Release Tab (Gx Aciphex®) 20mg	Gastrointestinal
4	Meropenem Injection (Gx Merrem®) 500mg/vial & 1g/vial	Antibiotic
5	Etomidate Injection (Gx Amidate®) 20mg/ml & 40mg/20ml	CNS
6	Abacavir Sulfate and Lamivudine Tab (Gx Epzicom®) 600/300mg	ARV
7	Dalfampridine Extended-Release Tab (Gx Ampyra®) 10mg	CNS
	Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol Tab (Gx Mircette®)	
8	0.15/0.02 mg & 0.01mg	Oral Contraceptive
	Guaifenesin and Dextromethorphan Hydrobromide Extended-Release	
9	Tablets (OTC) (Gx Mucinex® DM) 600/30mg and 1200/60mg	Respiratory
	Levetiracetam in Sodium Chloride Injection 500mg/10ml, 1,000mg/100ml	
10	and 1,500mg/100ml	CNS
	Tramadol Hydrochloride and Acetaminophen Tab (Gx Ultracet®) 37.5	
11	/325mg	Pain Relief
	Norethindrone and Ethinyl Estradiol and Ferrous Fumarate Chewable Tab	
12	(Gx FEMCON® Fe) 0.4/0.035mg and 75mg	Oral Contraceptive
13	Nevirapine Extended-Release Tab (Gx Viramune XR®) 400mg	ARV
14	Levalbuterol Inhalation Solution, Concentrate (Gx Xopenex®) 1.25mg/0.5ml	Respiratory

Tentative Approvals

1	Cinacalcet Tab (Gx Sensipar®) 30, 60 & 90mg	Calcium Regulator
2	Tenofovir Disoproxil Fumarate Tab (Gx Viread) 300mg	ARV

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Investor Relations

Krishna Kiran

Phone: 040-66725401 / 66725000

Mobile: +91 98486 67906

Email: ir@aurobindo.com

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Disclaimer:

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059**Regd. Off. :** Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.comwww.aurobindo.com

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2017						
		Quarter ended			Year Ended	
		31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
		Audited Refer note 4	Unaudited	Audited Refer note 4	Audited	Audited
1	Revenue from operations					
	(a) Net sales/income from operations (Inclusive of excise duty)	358,213	384,447	367,387	1,484,479	1,370,975
	(b) Other operating income	5,950	6,171	7,205	24,507	24,547
	Total revenue from operations (inclusive of excise duty)	364,163	390,618	374,592	1,508,986	1,395,522
2	Other Income					
	(a) Foreign exchange gain	1,903	1,580	1,534	6,205	13,367
	(b) Others	2,175	792	2,104	5,384	7,014
	Total other income	4,078	2,372	3,638	11,589	20,381
	Total income (1+2)	368,241	392,990	378,230	1,520,575	1,415,903
3	Expenses					
	(a) Cost of material consumed	127,942	130,059	123,230	518,492	482,556
	(b) Purchase of stock-in-trade	34,769	44,362	39,247	155,854	142,942
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(12,430)	(3,450)	113	(30,920)	(9,288)
	(d) Employee benefits expense	46,346	44,564	40,681	176,776	154,262
	(e) Finance costs	1,428	1,426	2,508	6,672	9,266
	(f) Foreign exchange Loss (refer note 8)	-	-	520	-	16,404
	(g) Depreciation and amortisation expense	10,005	11,114	11,140	42,763	39,237
	(h) Other expenses	95,412	85,599	84,691	345,356	306,239
	Total expenses	303,472	313,674	302,130	1,214,993	1,141,618
4	Profit before tax (1+2-3)	64,769	79,316	76,100	305,582	274,285
5	Share of profit/(loss) of joint venture	168	301	(13)	502	145
6	Profit /(Loss) from ordinary activities before tax (4+5)	64,937	79,617	76,087	306,084	274,430
7	Tax expense	11,715	21,767	20,636	75,964	72,071
8	Profit for the period (6-7)	53,222	57,850	55,451	230,120	202,359
9	Non controlling interest	(23)	(9)	(26)	(47)	(150)
10	Net Profit/(Loss) after taxes and non controlling interest (8-9)	53,245	57,859	55,477	230,167	202,509
11	Other Comprehensive income/(expense) - items that will not be reclassified to profit or loss (net of tax)	40	(281)	(39)	(579)	(147)
12	Total Comprehensive income for the period (10+11)	53,285	57,578	55,438	229,588	202,362
13	Paid-up equity share capital (face value Re. 1 per share)	5,859	5,852	5,852	5,859	5,852
14	Earnings per equity share of Re.1/- each (not annualised)					
	(a) Basic	9.10	9.88	9.49	39.33	34.67
	(a) Diluted	9.10	9.88	9.49	39.33	34.66

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com

www.aurobindo.com

NOTES:

- 1 The Company has adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder from April 1, 2016. The date of transition to Ind AS is April 01, 2015 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition has been accounted for in the opening reserves and the comparative period figures have been reinstated accordingly.
- 2 The above consolidated financial results have been prepared in accordance with principals and procedures as set out in the Ind AS 110 on "Consolidated financials statements" and Ind AS 28 on "Investment in Associate and Joint Venture" notified under section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on May 29, 2017.
- 4 The figures of the quarter ended March 31, 2017 and March 31, 2016 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2017 and March 31, 2016 respectively and the unaudited published year to date figures upto December 31, 2016 and December 31, 2015 respectively, being the date of the end of the third quarter of the financial year. The consolidated results for the nine months ended December 31, 2016 have been subjected to the limited review by the statutory auditors, but the financials results and other information for nine months ended December 31, 2015 have not been audited or reviewed by the statutory auditors. However, the management has exercised necessary due diligence to ensure that the unaudited financial results provide true and fair view of the Company's affairs.

5 The reconciliation of Net profit as previously reported (referred to as "Previous GAAP") and Ind AS is as under:

Particulars	Quarter ended March 31, 2016	Year ended March 31, 2016
Net profit under previous GAAP	56,285	198,200
Impact on deferred tax (including on unrealised intragroup profits on inventories)	251	2,116
Impact of foreign currency exchange differences	463	3,329
Difference in measurement of employee benefit expenses	26	189
Other Ind AS adjustments	(1,548)	(1,325)
Net profit for the period under Ind AS	55,477	202,509

6 The reconciliation of equity under Previous GAAP and Ind AS is as under:

Particulars	As at March 31, 2016
Equity reported under previous GAAP	699,822
Derecognition of provision for proposed dividend and dividend tax thereon	4,930
Impact on deferred tax (including on unrealised intragroup profits on inventories)	19,632
Other Ind AS adjustments	(1,506)
Equity under Ind AS	722,878

- 7 The Company's operates in only one segment viz. 'Pharmaceutical Products'.
- 8 Foreign exchange loss for standalone results includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- 9 During the quarter (i) Aurogen South Africa (PTY) LTD., a step down subsidiary was incorporated w.e.f January 25, 2017, (ii) Auro Vaccines LLC, USA, a step down subsidiary was incorporated w.e.f January 27, 2017, (iii) Aurovitas Pharma Polska Spolka, Poland, step down subsidiary was incorporated w.e.f. March 31, 2017.
- 10 The Company has allotted 697,823 equity shares of Re.1/- each on March 9, 2017 and 15,000 equity shares of Re.1/- each on March 30, 2017 to the employees under Employee Stock Option Plan 2006. Consequent to the allotment, the paid up share capital of the Company has increased from 585,169,586 to 585,882,409 equity shares of Re.1/- each.

By Order of the Board

Place: Hyderabad
Date : May 29, 2017

www.aurobindo.com

N.Govindarajan
Managing Director

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

Statement of consolidated assets and liabilities

(Rs. In lakhs)

Sl. No.	PARTICULARS	As at 31.03.2017	As at 31.03.2016
		(Audited)	(Audited)
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	408,305	338,039
	Capital work-in-progress	123,736	83,590
	Goodwill	40,630	40,630
	Other intangible assets	34,443	39,300
	Intangible assets under development	22,072	1,224
	Financial assets		
	Investments	24,585	12,294
	Loans	570	545
	Other financial assets	7,517	5,355
	Non current tax assets (net)	5,798	4,478
	Deferred tax assets (net)	16,776	20,628
	Other non-current assets	19,892	16,502
	Sub-total - Non-Current assets	704,324	562,585
2	Current assets		
	Inventories	433,054	405,614
	Financial assets		
	Investments	2	2
	Trade receivables	276,533	460,668
	Cash and cash equivalents	48,944	79,041
	Bank balances other than above	2,404	985
	Loans	1,089	1,031
	Financial assets - receivable from bank	73,885	-
	Other financial assets	1,880	4,918
	Current tax assets, net	1,751	425
	Other current assets	81,076	76,751
	Sub-total - Current assets	920,618	1,029,435
	TOTAL - ASSETS	1,624,942	1,592,020
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	5,859	5,852
	Other equity	931,332	722,878
	Non-controlling interest	208	255
	Sub-total - Equity	937,399	728,985
	Liabilities		
2	Non-current liabilities		
	Financial liabilities		
	Borrowings	18,140	74,281
	Provisions	2,241	2,336
	Deferred tax liability (net)	4,930	2,396
	Sub-total - Non-current liabilities	25,311	79,013
3	Current liabilities		
	Financial liabilities		
	Borrowings	290,272	367,268
	Trade payables	248,827	245,703
	Other financial liabilities	104,230	149,503
	Other current liabilities	9,915	8,255
	Provisions	6,342	5,092
	Current tax liabilities	2,646	8,201
	Sub-total - Current liabilities	662,232	784,022
	TOTAL EQUITY AND LIABILITIES	1,624,942	1,592,020

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com